Abstract 96P
Background
Archival storage of blood for single-cell (sc) RNA-Seq involves cryopreservation of peripheral blood mononuclear cells (PBMCs). However, this method excludes granulocytes and requires isolation of viable cells, whose transcriptomes may change due to processing time and technician handling. Hence, this method might overlook important data from temporal collection of clinical specimens. By contrast, blood collection in Qiagen PAXgene Blood RNA tubes is routinely practiced in medical sites without any special processing, and is completed with highly stabilized transcriptomes. Here, we present a novel method for single-nucleus (sn) RNA-Seq nuclei from frozen PAXgene blood as an alternative to PBMCs.
Methods
Fresh blood from healthy donors was collected, frozen in PAXgene tubes and processed by our novel method, which utilizes single-nucleus isolation and CRISPR-based strategy, yielding 3’RNA-Seq data via 10x Genomics’ Chromium platform. PBMCs from the same bloods were processed in parallel.
Results
Data quality evaluation revealed that PBMC transcript detection was higher than PAXgene, yet PAXgene RNA quality might exceed that of PBMCs. Unsupervised clustering was used to define cells and marker gene detection was used to assign cell types in PBMC and PAXgene data. Cell type subpopulations could be identified in PAXgene data, including central- and effector memory cells, and CD14+/16+ monocytes. Importantly, cells clustered based on cell type, indicating that sample biology was not masked by collection method. However, PAXgene specimens were distinct due to robust detection of granulocytes, including neutrophils (30-50% of blood cells). Proportions of PAXgene mononuclear cell populations were not significantly different from donor matched PBMCs. Results indicate that frozen PAXgene blood can be used to generate snRNA-Seq data that is comparable to PBMC scRNA-Seq, while also enabling transcriptomic characterization of granulocytes.
Conclusions
These findings provide preliminary evidence that PAXgene blood collection represents a simple, stable alternative to PBMC cryopreservation that could facilitate high quality, reproducible single-cell genomic profiling in clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AsatraZeneca.
Disclosure
A. Rotem, O. Chaudhary, G. Duclos, P. Gathungu, M. Rao, R. Aguilar, L. Amir-Zilberstein, V. Shankarappa, C. Rands, X. Chen, E. Galery Harbolick, R. Halpin, M. Steinberg, J. Boland, M. Scaltriti, B. Dougherty: Financial Interests, Full or part-time Employment: AstraZeneca.
Resources from the same session
83P - Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in eary high risk breast cancer: The CITUCEL trial update
Presenter: Roberto Borea
Session: Poster session 07
84P - Advancing precision oncology: Integrating immune landscape and genomics for tailored therapy in metastatic cancer patients
Presenter: Eurydice Angeli
Session: Poster session 07
85P - True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients
Presenter: Manoj Dongare
Session: Poster session 07
Resources:
Abstract
86P - Making the precision oncology landscape of Europe and the Republic of Ireland programmatically accessible
Presenter: Brendan Reardon
Session: Poster session 07
87P - Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making
Presenter: Fatima Usman
Session: Poster session 07
88P - Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry
Presenter: Christophe Le Tourneau
Session: Poster session 07
89P - Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial
Presenter: Ingrid Dyvik
Session: Poster session 07
90P - Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
Presenter: Pasquale Rescigno
Session: Poster session 07
91P - Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy
Presenter: Hao Liao
Session: Poster session 07
92P - Transformative diagnostics in urothelial carcinoma: Utilizing targeted NGS and LP-WGS for non-invasive detection and personalized medicine
Presenter: Huan Zhao
Session: Poster session 07